Clinical Efficacy of Huxinkang Pills on Patients with Unstable Angina Pectoris and Effects on Tumor Necrosis Factor-αand N-terminal Pro-brain Natriuretic Peptide
10.3969/j.issn.1005-5304.2016.03.005
- VernacularTitle:护心康片治疗冠心病不稳定型心绞痛临床疗效及对肿瘤坏死因子-α和N端脑钠肽的影响
- Author:
Guoqian WANG
;
Mincheng YU
;
Zhengke YU
;
Zhihong CHEN
;
Hongtu XIE
- Publication Type:Journal Article
- Keywords:
coronary heart disease;
unstable angina pectoris;
Huxinkang Pills;
tumor necrosis factor-α;
N-terminal pro-brain natriuretic peptide
- From:
Chinese Journal of Information on Traditional Chinese Medicine
2016;23(3):16-19
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy of Huxinkang Pills in treating patients with unstable angina pectoris (UAP) and its effects on the tumor necrosis factor-α (TNF-α) and N-terminal pro-brain natriuretic peptide (NT-proBNP). Methods Sixty patients with UAP were randomly divided into the treatment group and the control group, 30 cases in each group. Patients in the treatment group were treated with Huxinkang Pills based on the basic western medicine, while the patients in the control group were treated with Tongxinluo Capsules based on the basic western medicine. The treatment course was 4 weeks. Clinical efficacy and the change of the TNF-α and NT-proBNP levels before and after treatment were observed. Results The general efficacy, electrocardiograph efficacy, angina pectoris efficacy, TCM syndrome efficacy and glonoine reduction of the two groups had statistically difference (P<0.05) respectively, and the efficacy of the treatment group was superior to that of the control group (P<0.05). The TNF-α and NT-proBNP levels in both groups before and after treatment had statistically difference (P<0.05) respectively. The differences in TNF-α and NT-proBNP levels between both groups after treatment were all statistically significant (P<0.05), and these indexes of treatment group were superior to those of the control group (P<0.05). Conclusion Huxinkang Pills are remarkable in treating patients with UAP, and able to restrain the levels of TNF-α and NT-proBNP.
